CD33 and acute myeloid leukemia: Specifically, the combination of BM niche organoids with the proposed bispecific CAR technology could provide the ideal platform to further evaluate the specificity of this system against human CD146+ MSC and CD33+ AML cells within a humanized ossicle model (27).